Aurobindo Pharma Ltd is expanding its product portfolio in the US with high-value drugs.
“The portfolio mix is complemented with the introduction of high-value products and the future pipeline will include oncology, hormones, depot injections, inhalers, biosimilars, patches and films,’’ the Hyderabad-based company said in an investor presentation.
The addressable market for Aurobindo’s total 429 Abbreivated New Drug Applications (ANDAs) has been pegged at $91 billion, including $61 billion for the ANDAs which are under review and tentatively approved.
The gross revenue from the US market has been growing for the company at 40 per cent CAGR from ₹1,753 crore in FY13 to ₹6,827 crore in financial year ended March 31, 2017.
The growth drivers for the next four years include “broadening portfolio with more balance through accelerated growth in injectables, over the counter and higher complexity products,’’ it said.
The company also sees increasing scope for collaboration across global customers base.
New markets
For the European business, it has a pipeline of over 200 products and it is in the process of expanding to new markets such as Poland and the Czech Republic.
“Lower generics penetration in Italy, Spain, Portugal and France offer future growth potential as share of generics improves,’’ it said.
The portfolio expansion for the ₹15,090-crore drug maker (FY17) in Europe will be driven by targeted day-one launches spread across orals, hormones, penems, oncology, niche- and low-volume injectables,’’ it said.
In the domestic market, Aurobindo is among the top three listed companies in terms of sales.
